Meeting
2023 ASCO Genitourinary Cancers Symposium
Real world rates of genetic referrals and germline testing in patients with prostate adenocarcinoma at an academic cancer center in southern New Jersey.
Authors
Christopher Ambrogi
Cooper University Hospital, Camden, NJ
Christopher Ambrogi , Sahaj Desai , Randi Zukas Carhart , Jenia Jenab-Wolcott , Julia Chia-Ying Shih
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 114)
DOI
10.1200/JCO.2023.41.6_suppl.114
Abstract #
114
Poster Bd #
E3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Awareness of genetic risk for prostate cancer (PCa) in men from families with germline mutations in DNA-repair genes.
First Author: Massimo Lazzeri
Poster
2023 ASCO Genitourinary Cancers Symposium
A cohort study evaluating the clinical, environmental and genetic profiles of men with early-onset, aggressive prostate cancer.
First Author: Sarah Elizabeth Fenton
Poster
2022 ASCO Annual Meeting
Patient-reported outcomes among males undergoing prostate cancer germline testing: Interim results from the Prostate Cancer Genetic Risk, Experience, and Support Study (PROGRESS) Registry.
First Author: Veda N. Giri
Poster
2020 Gastrointestinal Cancers Symposium
Changing the landscape of germline testing in patients with pancreatic adenocarcinoma.
First Author: Aly Athens